Equities

Adimmune Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4142:TAI

Adimmune Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)18.05
  • Today's Change-0.20 / -1.10%
  • Shares traded2.37m
  • 1 Year change-24.63%
  • Beta0.4393
Data delayed at least 20 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.

  • Revenue in TWD (TTM)1.20bn
  • Net income in TWD-508.60m
  • Incorporated1965
  • Employees564.00
  • Location
    Adimmune CorpNo.3Section 1, Tanxing Road, Tanzi DistrictTAICHUNG 427TaiwanTWN
  • Phone+886 425381220
  • Fax+886 425382105
  • Websitehttps://www.adimmune.com.tw/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Formosa Pharmaceuticals Inc12.16m-74.25m4.10bn----2.71--336.98-0.5083-0.50830.081810.000.0057--4.64---3.49-30.53-3.80-33.884.52---610.20-758.219.55--0.0161--359.89163.5237.56--103.21--
Cenra Inc8.68bn293.68m5.08bn1.40k12.300.66637.970.58472.762.7678.3650.880.69761.985.75--2.373.493.584.7038.9636.763.395.220.72946.480.29450.314.012.28-1.53-3.78-8.434.92
Panion & BF Biotech Inc2.04bn174.37m5.28bn321.0030.312.7816.712.592.032.0323.7722.180.65111.729.45--5.573.468.144.9053.7452.048.555.280.836315.900.2529123.317.855.2261.26-5.0510.700.3601
Sinphar Pharmaceutical Co Ltd3.35bn345.57m5.81bn984.0016.841.769.871.741.811.8117.5717.390.54012.536.94--5.401.397.001.9142.5137.5910.003.111.5613.850.318869.666.335.64-18.7885.267.7540.11
SCI Pharmtech Inc1.39bn115.35m6.21bn241.0054.041.1617.004.470.96230.962311.6144.940.19741.604.99--1.645.961.897.0524.9135.308.3021.640.38412.560.150625.2426.54-8.3481.42-1.3135.86-18.67
Formosa Laboratories Inc4.90bn240.77m6.82bn480.0028.590.89489.231.391.981.9840.6363.360.35651.565.42--1.472.652.013.6041.8438.164.128.391.231.590.290841.088.5011.3824.5868.35-16.19--
Adimmune Corp1.20bn-508.60m7.75bn564.00--1.61--6.45-1.21-1.212.8511.210.14131.432.11---7.070.5893-8.860.67422.6732.30-50.052.711.42-49.730.402831.00-12.783.6862.06---15.71--
Standard Chem & Pharm Co Ltd6.91bn893.09m10.85bn1.13k12.161.826.561.574.994.9938.6333.290.60662.485.98--10.8010.4819.1819.4242.1443.8617.8118.241.69--0.103458.438.8111.515.4618.5227.4213.30
Data as of Feb 11 2026. Currency figures normalised to Adimmune Corp's reporting currency: Taiwan Dollar TWD

Institutional shareholders

4.01%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Jan 202612.64m2.94%
Dimensional Fund Advisors LPas of 08 Jan 20263.23m0.75%
SSgA Funds Management, Inc.as of 08 Jan 2026546.51k0.13%
Vanguard Fiduciary Trust Co.as of 30 Nov 2025386.77k0.09%
Vanguard Asset Management Ltd.as of 31 Dec 2025250.00k0.06%
Dimensional Fund Advisors Ltd.as of 30 Nov 2025104.15k0.02%
DFA Australia Ltd.as of 30 Nov 202537.93k0.01%
American Century Investment Management, Inc.as of 08 Jan 202614.00k0.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.